Our ADCC-enhanced antibody platform is one of the leading platforms in the world to enhance NK-cell function through antibody glycosylation modification. It also meets GMP manufacturing standards in China and has undergone clinical validation. We developed various clinical-stage or preclinical-stage antibody drug candidates using this platform, including MIL62 and MIL93 etc.
VIEW MORE
The distinctive features of our multi-specific antibody platform are biology function driven and structurally designed with enhanced flexibility and efficiency. The platform enables us to construct multi-specific antibodies quickly which facilitates the efficient production of multi-specific antibodies. Our multi-specific antibody platform enables us to develop antibodies simultaneously binding to different targets to achieve synergistic therapeutic functions. The major types of multi-specific antibody structure we are developing are set forth as below.
VIEW MORE
We have developed a proprietary antibody discovery and optimization platform that screens for antibodies with characterizes antibodies with enhanced binding affinity and stability, constructs antibodies specifically activated in the tumor environment, and design multi-specific antibodies with enhanced scFv stability.
VIEW MORE
